Tumor antigens, such as the carcinoembryonic antigen (CEA), a protein marker in the blood, increase the sensitivity and specificity to 18% in stage I, 35% in stage II, and approximately 50% in stage III as a general CRC screening test. This evidence concerns the gene CEACAM5 and colorectal carcinoma.